Slide 1: NeoStem, Inc. Investor Presentation January 2011
NEOSTEM, INC. (“NBS”) Investor Presentation January 2011
Slide 2: Forward-Looking Statements
I : 2 Forward-Looking Statements Kt Sh Tncluded in this presentation are “forward-looking” statements within the meaning of the Private Sacurites Litigation Reform Act of 1995, ac well as historical Information. Such forward-looking statements Involve known and unknown risks, uncertaintis and other
Slide 3: About NeoStem
2 About NeoStem NeoStem is a single source for collection, storage, manufacturing, therapeutic development and transporter of cells for cell based medicine and regenerative science globally. 51% ownership Progenitor Cell NeoStem’s China Research and in Suzhou Eyre Therapy Affiliated Entities Develop
Slide 4: Business Strategy
ae 3 : 2 Business Strategy Integrated Components build value with multiple revenue sources Propnetary Adult Seam Cell Products Develop comprehensive cord and adult stem cell banking business at cGMP quality Recurring revenue from annual storage fees Leverage expertise to cost effectively and efficie
Slide 5: Suzhou Erye — Profitable & Growing
3 Suzhou Erye — Profitable & Growing Acquired 51% of Chinese generic therapeutics company, Suzhou Erye) Location Suzhou China Suzhou Erye +" Vertically-integrated manufacturer of generic antibiotic products and APIs with extensive distribution throughout China — 8 cGMP-certified production lines — E
Slide 6: Regenerative Benefits of Autologous Stem Cells
2 Regenerative Benefits of Autologous Stem 3 Regeneration is the reactivation of : developmental processes to restore missing 3 or damaged tissues using stem cells H é ‘Evolutionary Scale Embryonic ‘Adi haral blood, bone matrow, cord blood, = isis Cees Risk of rejection: Yes No Risk of teratoma and
Slide 7: Agreement to buy 100% of Progenitor Cell Therapy (PCT)
In September 2010, NeoStem reached an agreement to buy 100% of Progenitor Cell Therapy (PCT) in an all-stock transaction. Expected close - January 19**, 2011 * Services include process and assay development, manipulation, cryopreservation, storage, 10 years of manufacturing and distribution experien
Slide 8: Reason for Merger
Reason for Merger: PCT acquisition creates scalability for NeoStem’s adult stem cell banking business and allows expansion of services to offer family blood banking program (cord blood and adult stem cell) at cGMP quality ona large scale - only company that has a comprehensive blood banking program
Slide 9: Progressive Stem Cell Environment in China
2 Progressive Stem Cell Environment in Cl * Favorable clinical and regulatory environment - Greater receptivity toward advanced therapeutics such as stem cell therapy - Actively seeking innovative technologies and therapies from the U.S. * Large and rapidly growing Chinese health care market going t
Slide 10: NeoStem's China Affiliated Entities
x NeoStem’s China Affiliated Entities 1.) Network of Hospitals delivering NeoStem’s Asia licensed Adult Stem Cell technology for Orthopedics using MSCs. 1.) Wendeng Hospital - Launched June 2010 2.) Shijianzhuag — Third Hospital signed December 2010 3.) A third hospital in Tianjin expected to sign e
Slide 11: Orthopedic Technology (Asia License)
Orthopedic Technology (Asia License) Fractures Before After Tibia Fracture Before After
Slide 12: Wound Technology (Worldwide License)
= 2 Wound Technology ( Worldwide License) — Melanoma “ mi fd Double barreled syringe Back wound after surgery Spraying adult stem Wound completely healed tospray adult stem cells" to Remove skin cancer cells Into the wound ‘after 7 months Foot Baseline During 3 Application, Almost Healed at 3 months
Slide 13: Proprietary Cell, Formulation and Delivery Technology
2 Proprietary Cell, Formulation and Delivery Technology Developing cellular therapy platform to generate revenues today and serve as a vehicle for expansion Proprietary Technology Cells Used Currently Potential Future Indication Advancements Orthopedics Mscs VSELs™ Wound MSCs VSELs™ ‘Cosmetic/Skin R
Slide 14: VSEL Technology is NeoStem's proprietary adult stem cell technology
VSEL™ Technology is NeoStem’s proprietary adult stem cell technology with an exclusive worldwide license from the University of Louisville Mobilization of Bone Marrow-Derived Gct-A SSEA-4+ Very Smal Embryonic Like Stem Cells In Patients Isolated from a patients own bone marrow, peripheral as ocr ran
Slide 15: Validating Partnerships
e Validating Partnerships = Academic Collaborators of NeoStem for VSEL Development + Sponsored research agreement with University of California-Davis + Sponsored research agreement with the Schepens Eye Research Institute, an affiliate of Harvard * Sponsored research agreement with University of Lou
Slide 16: NeoStem Management Team
Robin Smith, MD MBA CEO 8 Chairman of the Board 3ian Zhang General Manager, Suzhou Erye Pharmaceuticals Co, Ltd ‘an Zhang, PhD MBA President and Managing Director INeoStem (China), Inc Larry May (Chie? Financial Officer Catherine Vaczy, Esq VP and General Couns! Alan Harris, MD Pho FACP FRCP VP, Reg
Slide 17: Board of Directors
4 2 Board of Directors NeoStem Board Members MD ~ Yale; MBA - Wharton Robin Smith, MD, MBA. CEO & Chairman of the + Formerly President & CEO IP2M (HC multimedia), EVP & CMO HealthHelp (radiology management) Board + Trustee of NYU Medical Center; Chairman of the Board of NYU Hospital for Joint Diseas
Slide 18: NeoStem Capitalization Table
NeoStem Capitalization Table Capitalization (Common Share Equivalent in 000s) Shares Outstanding % Outstanding ‘Common Stock 64,120 61.4% Total Preferred Shares (common share equivalents) 5,300" 54 Total Warrants (average exercise price $2.62) 21,843 209 Total Options (average exercise price $1.91)
Slide 19: Key Financial Metrics
Key Financial Metrics) Historical Income Statement ($ 000's)| Balance Sheet ($ 00's) ‘Months Ending AS of 9130/40 930/10 Revenue Cash & equivalents $ 4,067 Pharmaceuticals $51,500 Guetasce § 28.258 Stem cell and others —— Total assets $116,971 Hcp revences ES Current labilties $ 20,570 Soe yom 180m
Slide 20: Goals of NeoStem
2 Goals of NeoStem + Advancing proprietary technology in cellular therapy + Developing Education program with Pontifical Council of the Vatican on importance of Adult Stem Cell research, therapeutic development and banking treatments (launch November 2011) + Continue Strategic activities to drive va
Slide 21: Contact Information
Contact Information NeoStem, Inc. Robin Smith, MD, MBA Chairman & CEO Phone: (212) 584-4174 Email: rsmith@neostem.com http://www.neostem.com 21